MGI(SH:688114) Huaan Securities·2024-11-02 22:36Investment Rating - The investment rating for the company is "Buy" (maintained) [1][2] Core Views - The company reported a revenue of 1.869 billion yuan for the first three quarters of 2024, a year-on-year decrease of 15.19%, with a net profit attributable to shareholders of -463 million yuan [1] - In Q3 2024, the company achieved a revenue of 660 million yuan, down 13.22% year-on-year, attributed to weak domestic research budgets and non-essential medical demand, compounded by geopolitical tensions affecting overseas expansion [1] - The company has a strong market position in the domestic market, with expectations for a recovery in domestic demand due to large-scale equipment renewal policies from government departments [1] - The company has established nine major R&D centers, seven production bases, and nine international warehouses globally, enhancing its overseas business layout [1] Financial Summary - For 2024E, the company is expected to generate revenues of 2.727 billion yuan, with a year-on-year decrease of 6.3% [4] - The net profit attributable to shareholders is projected to improve from -607 million yuan in 2023A to -395 million yuan in 2024E, with a year-on-year growth of 35.0% [4] - The gross margin is expected to increase from 59.5% in 2023A to 63.0% in 2024E [4] - The company anticipates a gradual recovery in profitability, with net profits projected to turn positive by 2026E [4][6]